2. Search Result
Search Result
Results for "

Parasitemia

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16779
    Fosravuconazole

    BMS-379224; E-1224

    		 Fungal Parasite Infection
    Fosravuconazole (BMS-379224), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole can be used for candidiasis, onychomycosis and parasitemia research .
    Fosravuconazole
  • HY-16779B
    Fosravuconazole L-lysine ethanolate

    BMS-379224 L-lysine ethanolate; E-1224 L-lysine ethanolate

    		 Fungal Parasite Infection
    Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research .
    Fosravuconazole L-lysine ethanolate
  • HY-136448
    SJ000025081

    		Parasite Infection
    SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent. SJ000025081 results in an obvious suppression of the parasitemia in a murine malaria model infected with P. yoelii .
    SJ000025081
  • HY-120489
    A110

    		Parasite Infection
    A110 is the inhibitor for Cryptosporidium parvum inosine monophosphate dehydrogenase (CpIMPDH). A110 inhibits CpIMPDH in Toxoplasma gondii with IC50 of 18 nM. A110 exhibits pro-parasitic efficacy and cause parasitemia .
    A110
  • HY-149938
    Antimalarial agent 25

    		Parasite Infection
    Antimalarial agent 25 is an orally active 1,4-naphthoquinones derivative with antimalarial activity. Antimalarial agent 25 shows cytotoxicity against P. falciparum. Antimalarial agent 25 inhibits P. burghei induced parasitemia in vivo .
    Antimalarial agent 25
  • HY-149939
    Antimalarial agent 26

    		Parasite Infection
    Antimalarial agent 26 is an orally active 1,4-naphthoquinones derivative with antimalarial activities. Antimalarial agent 26 shows cytotoxicity against P. falciparum and selectivity over mammalian cell lines. Antimalarial agent 26 inhibits P. burghei induced parasitemia in vivo .
    Antimalarial agent 26
  • HY-148177
    Sutidiazine

    ZY-19489; MMV 253; AZ13721412

    		 Parasite Infection
    Sutidiazine (ZY-19489) is an orally active and antimalarial agent. Sutidiazine inhibits parasitemia-induced infection. Sutidiazine shows short half-lives (approximately 7 h) and an exposure effect .
    Sutidiazine
  • HY-161384
    WJM-715

    		Parasite Infection
    WJM-715 is an antimalarial agent with an EC50 of 0.015 μM by trageting STAR-related lipid transfer protein (PfSTART1) with a KD of 14 nM .
    WJM-715
  • HY-172953
    Insecticidal agent 24

    		Parasite Infection
    Insecticidal agent 24 is an orally active pyridylspiroindoline frontrunner. Insecticidal agent 24 has antiplasmodial activity (Pf NF54 IC50: 0.08 μM). Insecticidal agent 24 inhibits hERG activity (IC50: 6.5 μM). Insecticidal agent 24 reduces parasitemia in a humanized immunodeficient NSG mouse Plasmodium falciparum infection model .
    Insecticidal agent 24
  • HY-B1896
    Piperaquine

    		Parasite Infection
    Piperaquine is a bisquinoline antimalarial agent. Piperaquine can be used in antimalarial research in combination with Artemisinin .
    Piperaquine
  • HY-174325
    Antimalarial agent 50

    		Parasite Infection Inflammation/Immunology
    Antimalarial agent 50 is an antiplasmodial compound. Antimalarial agent 50 has an effect against Plasmodium berghei induced malaria infection in mice model. Antimalarial agent 50 can regulate oxidative stress and significantly reduce the levels of inflammatory factors. Antimalarial agent 50 can be used for the research of the malaria[1].
    Antimalarial agent 50
  • HY-147849
    JMI-105

    		Parasite Infection
    JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQ S (3D7; IC50=8.8 µM) and CQ R (RKL-9; IC50=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent .
    JMI-105

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: